KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $69.4 million.

  • BeOne Medicines' Gains from Investment Securities fell 67.96% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.6 million, marking a year-over-year increase of 38.60%. This contributed to the annual value of $69.4 million for FY2024, which is 23.98% up from last year.
  • Latest data reveals that BeOne Medicines reported Gains from Investment Securities of $69.4 million as of FY2024, which was up 23.98% from $56.0 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Gains from Investment Securities registered a high of $191.1 million during FY2021, and its lowest value of $10.6 million during FY2020.
  • For the 3-year period, BeOne Medicines' Gains from Investment Securities averaged around $51.6 million, with its median value being $56.0 million (2023).
  • Per our database at Business Quant, BeOne Medicines' Gains from Investment Securities spiked by 1,703.63% in 2021 and then tumbled by 84.56% in 2022.
  • Over the past 5 years, BeOne Medicines' Gains from Investment Securities (Yearly) stood at $10.6 million in 2020, then soared by 1,703.63% to $191.1 million in 2021, then plummeted by 84.56% to $29.5 million in 2022, then soared by 89.84% to $56.0 million in 2023, then climbed by 23.98% to $69.4 million in 2024.